Literature DB >> 19051304

Controlled release of FGF-2 using fragmin/protamine microparticles and effect on neovascularization.

Shingo Nakamura1, Yasuhiro Kanatani, Satoko Kishimoto, Shin-ichiro Nakamura, Chizuko Ohno, Takuya Horio, Fujita Masanori, Hidemi Hattori, Yoshihiro Tanaka, Tomoharu Kiyosawa, Tadaaki Maehara, Masayuki Ishihara.   

Abstract

Water-insoluble fragmin/protamine microparticles of about 0.5-1 mum in diameter were prepared by simple mixing of low-molecular-weight heparin (fragmin) with protamine. We investigated the capability of these microparticles to immobilize fibroblast growth factor (FGF)-2, to protect FGF-2 against degradation, to enhance FGF-2 activity, and to facilitate controlled release of FGF-2. FGF-2 bound to the fragmin/protamine microparticles with high affinity (Kd = 2.08 x 10(-9) M) and the half-life of FGF-2-activity was prolonged substantially through binding of FGF-2 to the microparticles, by protection of FGF-2 from inactivation by heat and proteolysis. After subcutaneous injection into the back of mice, the fragmin/protamine microparticles underwent biodegradation and disappeared in about 2 weeks. A similar injection of FGF-2-containing microparticles resulted in significant neovascularization and fibrous tissue formation near the injection site after 1 week. These results indicate that controlled release of biologically active FGF-2 occurs through both slow diffusion and biodegradation of the microparticles, with subsequent induction of neovascularization. (c) 2008 Wiley Periodicals, Inc. J Biomed Mater Res, 2009.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19051304     DOI: 10.1002/jbm.a.32265

Source DB:  PubMed          Journal:  J Biomed Mater Res A        ISSN: 1549-3296            Impact factor:   4.396


  19 in total

1.  Three-dimensional culture using human plasma-medium gel with fragmin/protamine microparticles for proliferation of various human cells.

Authors:  Satoko Kishimoto; Masayuki Ishihara; Makoto Takikawa; Megumi Takikawa; Yuki Sumi; Shingo Nakamura; Masanori Fujita; Toshinori Sato; Tomoharu Kiyosawa
Journal:  Cytotechnology       Date:  2013-08-17       Impact factor: 2.058

2.  Delivery system for autologous growth factors fabricated with low-molecular-weight heparin and protamine to attenuate ischemic hind-limb loss in a mouse model.

Authors:  Shingo Nakamura; Megumi Takikawa; Masayuki Ishihara; Takefumi Nakayama; Satoko Kishimoto; Susumu Isoda; Yuichi Ozeki; Masahiro Sato; Tadaaki Maehara
Journal:  J Artif Organs       Date:  2012-08-14       Impact factor: 1.731

3.  Attenuation of limb loss in an experimentally induced hindlimb ischemic model by fibroblast growth factor-2/fragmin/protamine microparticles as a delivery system.

Authors:  Shingo Nakamura; Masayuki Ishihara; Megumi Takikawa; Satoko Kishimoto; Susumu Isoda; Masanori Fujita; Masahiro Sato; Tadaaki Maehara
Journal:  Tissue Eng Part A       Date:  2012-08-16       Impact factor: 3.845

4.  Preparation and characterization of low-molecular-weight heparin/protamine nanoparticles (LMW-H/P NPs) as FGF-2 carrier.

Authors:  Yasutaka Mori; Shingo Nakamura; Satoko Kishimoto; Mitsuyuki Kawakami; Satoshi Suzuki; Takemi Matsui; Masayuki Ishihara
Journal:  Int J Nanomedicine       Date:  2010-04-07

5.  Selective Expansion of CD34+ Cells from Mouse Bone Marrow Cultured on LH/P MP-Coated Plates with Adequate Cytokines.

Authors:  Satoko Kishimoto; Masayuki Ishihara; Yasuhiro Kanatani; Masaki Nambu; Megumi Takikawa; Yuki Sumi; Shingo Nakamura; Yasutaka Mori; Hidemi Hattori; Yoshihiro Tanaka; Toshinori Sato
Journal:  J Tissue Eng       Date:  2011-10-30       Impact factor: 7.813

6.  Adequate Selection of a Therapeutic Site Enables Efficient Development of Collateral Vessels in Angiogenic Treatment With Bone Marrow Mononuclear Cells.

Authors:  Masaru Nemoto; Hiroyuki Koyama; Ayako Nishiyama; Kunihiro Shigematsu; Tetsuro Miyata; Toshiaki Watanabe
Journal:  J Am Heart Assoc       Date:  2015-09-14       Impact factor: 5.501

Review 7.  Biomedical application of low molecular weight heparin/protamine nano/micro particles as cell- and growth factor-carriers and coating matrix.

Authors:  Masayuki Ishihara; Satoko Kishimoto; Makoto Takikawa; Hidemi Hattori; Shingo Nakamura; Masafumi Shimizu
Journal:  Int J Mol Sci       Date:  2015-05-22       Impact factor: 5.923

8.  Improvement of hydrodynamics-based gene transfer of nonviral DNA targeted to murine hepatocytes.

Authors:  Shingo Nakamura; Tadaaki Maehara; Satoshi Watanabe; Masayuki Ishihara; Masahiro Sato
Journal:  Biomed Res Int       Date:  2013-03-17       Impact factor: 3.411

9.  Three-dimensional expansion using plasma-medium gel with fragmin/protamine nanoparticles and fgf-2 to stimulate adipose-derived stromal cells and bone marrow-derived mesenchymal stem cells.

Authors:  Satoko Kishimoto; Masayuki Ishihara; Yasutaka Mori; Megumi Takikawa; Yuki Sumi; Shingo Nakamura; Toshinori Sato; Tomoharu Kiyosawa
Journal:  Biores Open Access       Date:  2012-12

Review 10.  Cellular and pharmacological targets to induce coronary arteriogenesis.

Authors:  Maurits R Hollander; Anton J G Horrevoets; Niels van Royen
Journal:  Curr Cardiol Rev       Date:  2014-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.